Evaxion Biotech A/S announced positive preclinical data for its cytomegalovirus (CMV) vaccine program, EVX-V1, on November 12, 2024. The data, presented at the 9th International Conference on Vaccines Research & Development, showed that antigens identified by Evaxion’s AI-Immunology platform effectively triggered targeted immune responses, including both CMV reactive B and T cells.
The company also designed a proprietary prefusion gB antigen, a known CMV vaccine component, which successfully induced a specific immune response comparable to that of the conventional gB antigen. Evaxion plans to combine these AI-Immunology identified antigens with its proprietary prefusion gB antigen in a future vaccine candidate.
This novel multi-target approach aims to enhance vaccine efficacy by combating the virus from numerous angles, differentiating it from traditional methods that focus on a limited set of glycoproteins. The data brings Evaxion closer to developing an effective CMV vaccine, a disease for which no approved vaccine currently exists.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.